◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › KPRX

Kiora Pharmaceuticals, Inc. (KPRX) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-20

Kiora Pharmaceuticals, Inc. (KPRX) operates in the Biotechnology industry and is headquartered in Encinitas, United States with about 13 employees. Its market capitalization is roughly $12 million. In the fiscal year ended 2025-12-31, KPRX reported $0M in revenue and ($11M) in net income.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases.

Interactive charts & full statements →

KPRX Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$16M$0M$0M
Operating Income (EBIT)($10M)$6M($9M)($12M)
Net Income($11M)$4M($12M)($14M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KPRX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($2M)($3M)($2M)($2M)($2M)
Net Income($2M)($6M)$0M($2M)($2M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KPRX Free Cash Flow History

KPRX Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$24M$36M$14M$19M
Total Liabilities$8M$11M$8M$7M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KPRX viewer.

Other Companies in Biotechnology

← KPLTAll stocksKPTI →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.